NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo

Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment of relapsed or refractory MM patients.

Multiple Locations

ClinicalTrials.gov Identifier: NCT02612779

Official Title: A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

---

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Elotuzumab : National Cancer Institute

Elotuzumab : MedlinePlus Drug Information

Pomalidomide : National Cancer Institute

Pomalidomide : MedlinePlus Drug Information

Nivolumab : National Cancer Institute

Nivolumab : MedlinePlus Drug Information